Additionally, we demonstrate that the oncogenic activity of PCAT6 is attributable to the ceRNA regulatory network of the PCAT6-miR-143-3p-TAK1 axis, which is a potential therapeutic target for ovarian cancer. This evidence concerns the gene MAP3K7 and ovarian carcinoma.